Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Whitfield

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Journal of Biological Chemistry|February 9, 2006
Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivoTobias B Dansen, Jonathan Whitfield, Fanya Rostker, et al.
Cardiovascular Therapeutics|June 10, 2014
Prescribers' practice of assessing arrhythmia risk with QT-prolonging medicationsWai Kah Choo, David Turpie, Kim Milne, et al.
Nature|August 22, 2008
Modelling Myc inhibition as a cancer therapyLaura Soucek, Jonathan Whitfield, Carla P Martins, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 11, 2024
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugateSandra Bibbò, Emily Capone, Giulio Lovato, et al.
Bioorganic & Medicinal Chemistry Letters|September 13, 2005
The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffoldPiotr P Graczyk, Afzal Khan, Gurpreet S Bhatia, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Journal of Biological Chemistry|February 9, 2006
Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivoTobias B Dansen, Jonathan Whitfield, Fanya Rostker, et al.
Cardiovascular Therapeutics|June 10, 2014
Prescribers' practice of assessing arrhythmia risk with QT-prolonging medicationsWai Kah Choo, David Turpie, Kim Milne, et al.
Nature|August 22, 2008
Modelling Myc inhibition as a cancer therapyLaura Soucek, Jonathan Whitfield, Carla P Martins, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 11, 2024
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugateSandra Bibbò, Emily Capone, Giulio Lovato, et al.
Bioorganic & Medicinal Chemistry Letters|September 13, 2005
The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffoldPiotr P Graczyk, Afzal Khan, Gurpreet S Bhatia, et al.
Pageof 2